Through these comprehensive datasets, we find that PRAD and NEPC tumors display a high degree of phenotypic heterogeneity with an array of androgen receptor (AR) positive and negative, and NEPC gene regulatory networks (GRNs). Here, AR is linked to prostate adenocarcinoma.